GE Healthcare Presents at JP Morgan Healthcare Conference on Role of Molecular and Companion Diagnostics in Personalized M

Medical Diagnostics CEO Pascale Witz Addresses Conference

PRINCETON, N.J.--(BUSINESS WIRE)-- Pascale Witz, President and CEO, GE Healthcare, Medical Diagnostics discussed diagnostics as the future of personalized medicine at the 30th JP Morgan Healthcare Conference in San Francisco, CA. During her presentation, Witz noted that diagnostics and pathology screening are core enablers of personalized medicine, and outlined how GE Healthcare partners with the pharmaceutical industry to support market entry of new therapies via providing complex technologies that can aid in the conduct of clinical trials, potentially expediting time to market.

“Personalized medicine is at the core of our efforts in medical diagnostics,” Witz said. “We are working to combine in vivo and in vitro testing for integrated solutions from risk stratification and early detection through prediction and monitoring. The combination of our different business offerings positions us well to offer an integrated global diagnostics solution for the next generation of therapies.”

Witz’s talk focused specifically on GE Healthcare’s existing work in oncology and the Company’s commitment to expand its advanced cancer diagnostic and molecular imaging capabilities. With its advanced technologies, GE Healthcare’s Clarient business is able to provide pathologists and oncologists with accurate and detailed information to help characterize and assess cancer which may lead to more accurate diagnoses and more effective treatment. Witz also discussed Omnyx, a joint venture between GE Healthcare and the University of Pittsburgh, which is developing an Integrated Digital Pathology system allowing pathology departments worldwide to move to an all-digital workflow.

A link to Witz’s presentation is available at GE’s Investor Relations website at


GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at

For our latest news, please visit


GE Healthcare
Aleisia Gibson
609-514-6046 (office)
609-865-4004 (mobile)
[email protected]
Scott Lerman
609-514-6346 (office)
609-937-9352 (mobile)
[email protected]

KEYWORDS:   United States  North America  California  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science  General Health